FOR THE NEXT GENERATION OF PHYSICIANS
← All USMLE guides
PHARMACOLOGY

Drug development and clinical trial phases.

Phases I to IV, Orphan drug rules, postmarketing surveillance, bioequivalence and basic trial terminology for USMLE.

Clinical trial phases are tested as a ladder: safety, efficacy, large comparison, then surveillance.

Phases

Phase 0 uses micro-doses. Phase I tests safety and pharmacokinetics in a small group of healthy volunteers (or patients for toxic drugs). Phase II tests efficacy and dosing in a small group of patients. Phase III compares the drug with standard care in large randomized trials. Phase IV is postmarketing surveillance for rare adverse events.

Concepts

Therapeutic index equals toxic dose divided by effective dose; a narrow index needs drug level monitoring (digoxin, lithium, warfarin, aminoglycosides, theophylline). Potency refers to the dose for an effect; efficacy is the maximum effect. Partial agonists have lower efficacy and can act as antagonists.

Regulation

A new drug application follows trials. Generic drugs must be bioequivalent. Black box warnings flag serious risks.

Keep going in pharmacology

Related on USMLE WEB

Frequently asked questions

Which phase tests safety in healthy volunteers?

Phase I.

Which phase detects rare adverse events after approval?

Phase IV.